2,389 results on '"Kumada, Hiromitsu"'
Search Results
252. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients
253. Transcatheter Arterial Chemotherapy Using Miriplatin–Lipiodol Suspension with or without Embolization for Unresectable Hepatocellular Carcinoma
254. Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b–infected null responders
255. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B
256. Clinical and virological features of chronic hepatitis C carriers with normal alanine aminotransferase levels despite positive serum HCV-RNA after interferon therapy
257. Enzyme-linked immunosorbent assay to detect hepatitis C virus serological groups 1 to 6
258. Effect of arterial administration of a high-molecular weight antitumor agent, styrene maleic acid neocarzinostatin, in embolization-resistant liver cancer
259. Predictive value of different hepatitis C serological assays in the treatment of chronic hepatitis C with interferon α
260. Highly sensitive AFP-L3% assay is useful for predicting recurrence of hepatocellular carcinoma after curative treatment pre- and postoperatively
261. Cancer preventive effect of pegylated interferon α-2b plus ribavirin in a real-life clinical setting in Japan: PERFECT interim analysis
262. Development rate of chronic kidney disease in hepatitis C virus patients with advanced fibrosis after interferon therapy
263. Efficacy and safety in sitagliptin therapy for diabetes complicated by chronic liver disease caused by hepatitis C virus
264. Amino Acid Substitutions in Hepatitis C Virus Core Region Predict Hepatocarcinogenesis Following Eradication of HCV RNA by Antiviral Therapy
265. Common Genetic Polymorphism of ITPA Gene Affects Ribavirin-Induced Anemia and Effect of Peg-Interferon Plus Ribavirin Therapy
266. Stage progression of small hepatocellular carcinoma after radical therapy: comparisons of radiofrequency ablation and surgery using the Markov model
267. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy
268. Influence of Itpa Polymorphisms on Decreases of Hemoglobin During Treatment With Pegylated Interferon, Ribavirin, And Telaprevir
269. Management of hepatitis B: Consensus of the Japan Society of Hepatology 2009
270. Potential and Clinical Significance of 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography for Evaluating Liver Cancer Response to Lenvatinib Treatment
271. Cover Image, Volume 92, Number 12, December 2020
272. Diagnosis and Resection Treatment of Triplet Hepatocellular Carcinomas with a non-B non-C Background in a Middle Aged Man over a Period of 6-years
273. Effects of alcohol consumption on multiple hepatocarcinogenesis in patients with fatty liver disease
274. TERT Promoter Mutation in Serum Cell-Free DNA Is a Diagnostic Marker of Primary Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease
275. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma
276. SGLT2 Inhibitor Treatment Outcome in Nonalcoholic Fatty Liver Disease Complicated with Diabetes Mellitus: The Long-term Effects on Clinical Features and Liver Histopathology
277. A phase 1b study of lenvatinib plus pembrolizumab in unresectable hepatocellular carcinoma
278. Hepatitis B core-related antigen and viral loads status impacts on the risk of hepatocellular carcinoma in patients with HBeAg-negative chronic hepatitis B virus infection
279. Fulminant Hepatitis due to de novo Hepatitis B after Cord Blood Transplantation Rescued by Medical Treatment
280. A phase Ib study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC).
281. Advantage of liver stiffness measurement before and after direct‐acting antiviral therapy to predict hepatocellular carcinoma and exacerbation of esophageal varices in chronic hepatitis C
282. Detection of TERT promoter mutation in serum cell‐free DNA using wild‐type blocking PCR combined with Sanger sequencing in hepatocellular carcinoma
283. A phase Ib study of lenvatinib (LEN) plus nivolumab (NIV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study 117.
284. Predictors of Insulin Secretion in Japanese Patients with Histopathologically-confirmed Non-alcoholic Fatty Liver Disease
285. Poorly Differentiated Hepatocellular Carcinoma in a Low-risk Patient with an Otherwise Normal Liver
286. Pretreatment Heterogeneous Enhancement Pattern of Hepatocellular Carcinoma May Be a Useful New Predictor of Early Response to Lenvatinib and Overall Prognosis
287. Long-term histological impact of sodium-glucose co-transporter-2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus: 3 cases evaluated by liver histology at 3 years after the start of treatment
288. Lenvatinib-Transarterial Chemoembolization Sequential Therapy as an Effective Treatment at Progression during Lenvatinib Therapy for Advanced Hepatocellular Carcinoma
289. Administration of interferon for two or more years decreases early stage hepatocellular carcinoma recurrence rate after radical ablation: A retrospective study of hepatitis C virus-related liver cancer
290. Accumulation of refractory factors for pegylated interferon plus ribavirin therapy in older female patients with chronic hepatitis C
291. HBcrAg is a predictor of post-treatment recurrence of hepatocellular carcinoma during antiviral therapy
292. New classification of dynamic computed tomography images predictive of malignant characteristics of hepatocellular carcinoma
293. A Cost-Effectiveness Analysis of Glecaprevir/Pibrentasvir Versus Existing Direct-Acting Antivirals to Treat Chronic Hepatitis C in Japan
294. Treatment of patients with resistant mutants against nucleos(t)ide analogs: Plenary Session 5: Treatment (Resistant Mutants against NA)
295. Efficacy of switching to entecavir monotherapy in Japanese lamivudine-pretreated patients
296. Management of hepatitis C; Report of the Consensus Meeting at the 45th Annual Meeting of the Japan Society of Hepatology (2009)
297. Virus Clearance Reduces Bone Fracture in Postmenopausal Women With Osteoporosis and Chronic Liver Disease Caused by Hepatitis C Virus
298. Correlation of YMDD mutation and breakthrough hepatitis with hepatitis B virus DNA and serum ALT during lamivudine treatment
299. Development of HCC in patients receiving adefovir dipivoxil for lamivudine-resistant hepatitis B virus mutants
300. Prolonged treatment with pegylated interferon α 2b plus ribavirin improves sustained virological response in chronic hepatitis C genotype 1 patients with late response in a clinical real-life setting in Japan
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.